Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma.

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00363 JCO Precision Oncology no. 7 (2023) e2200363. Published online May 24, 2023. PMID: 37224427 Exceptional Response to Dual Colony-Stimulating Factor 1 Receptor/PD-L1 Targeting After Primary Resistance to PD-1 Inhibition in a Patient With a Metastatic Uveal Melanoma Stéphane Champiat , MD, PhD1,2,3xStéphane ChampiatSearch for articles by this author; Hélène Salaün, MD4xHélène SalaünSearch for articles by this author; Francesca Lucibello, MD, PhD5xFrancesca LucibelloSearch for articles by this author; Jean-Yves Scoazec , MD, PhD6xJean-Yves ScoazecSearch for articles by this author; Benjamin Besse , MD, PhD7xBenjamin BesseSearch for articles by this author; Ana Ines Lalanne, PhD8,9xAna Ines LalanneSearch for articles by this author; Etienne Rouleau , MD, PhD6xEtienne RouleauSearch for articles by this author; Nolwenn Metzger , BSc10xNolwenn MetzgerSearch for articles by this author; Mathilde Saint-Ghislain, MD4xMathilde Saint-GhislainSearch for articles by this author; Thomas Ryckewaert, MD11xThomas RyckewaertSearch for articles by this author; Sophie Gardrat, MD11,12xSophie GardratSearch for articles by this author; Raymond Barnhill , MD, PhD13xRaymond BarnhillSearch for articles by this author; Nathalie Cassoux, MD, PhD14xNathalie CassouxSearch for articles by this author; Marc-Henri Stern , MD, PhD12xMarc-Henri SternSearch for articles by this author; Olivier Lantz, MD, PhD5,8,9xOlivier LantzSearch for articles by this author; Leanne de Koning , PhD13xLeanne de KoningSearch for articles by this author; Aurélien Marabelle , MD, PhD1xAurélien MarabelleSearch for articles by this author; and Manuel Rodrigues , MD, PhD4,12xManuel RodriguesSearch for articles by this author Show More 1Drug Development Department, Gustave Roussy Comprehensive Cancer Center, Villejuif, France2Department of Translational Research, University Paris-Saclay, Inserm U1015, Villejuif, France3University Paris-Saclay, Inserm, Clinical Investigation Center (CIC-BT1428) Biotheris, Villejuif, France4Medical Oncology Department, PSL Research University, Institut Curie, Paris, France5Center for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research University, Paris, France6Department of Biopathology, University Paris-Saclay, Gustave Roussy Cancer Center, Villejuif, France7Paris Saclay University, Department of Cancer Medicine, Gustave Roussy, Villejuif, France8Clinical Immunology Laboratory, Institut Curie, Paris, France9Clinical Investigation Center (CIC-BT1428), Institut Curie, Paris, France10Department of Somatic Genetics, Institut Curie, PSL Research University, Paris, France11Department of Medical Oncology, Centre Oscar Lambret, Lille, France12Unit 830 (Cancer, Heterogeneity, Instability and Plasticity) INSERM, Institut Curie, PSL Research University, Paris, France13Department of Translational Research, Institut Curie, PSL Research University, Paris, France14Department of Ophthalmology, Institut Curie, PSL Research University, Paris, France*S.C., H.S., and F.L. are coprimary authors. https://doi.org/10.1200/PO.22.00363 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologySUPPORTM.R. was supported by the Interface INSERM program. The MATCH-R trial was supported by a Natixis foundation grant, a Philanthropy Lombard-Odier foundation grant, and Gustave Roussy Foundation. MOSCATO trial was supported by Gustave Roussy Foundation (Revolution Cancer initiative), INCa-DGOS-INSERM 6043 (SIRIC SOCRATE), and ANR-10-IBHU-0001 (MMO) and received an unrestricted grant from Genentech and Sanofi.DATA SHARING STATEMENTThe data that support the findings of this study are available upon reasonable request to the corresponding author, M.R.AUTHOR CONTRIBUTIONSConception and design: Stéphane Champiat, Hélène Salaün, Jean-Yves Scoazec, Olivier Lantz, Aurélien Marabelle, Manuel RodriguesProvision of study materials or patients: Stéphane Champiat, Jean-Yves Scoazec, Etienne Rouleau, Nathalie Cassoux, Aurélien MarabelleCollection and assembly of data: Stéphane Champiat, Hélène Salaün, Francesca Lucibello, Jean-Yves Scoazec, Mathilde Saint-Ghislain, Thomas Ryckewaert, Sophie Gardrat, Nathalie Cassoux, Aurélien Marabelle, Manuel RodriguesData analysis and interpretation: Stéphane Champiat, Jean-Yves Scoazec, Benjamin Besse, Ana Ines Lalanne, Etienne Rouleau, Nolwenn Metzger, Raymond Barnhill, Marc-Henri Stern, Olivier Lantz, Leanne de Koning, Aurélien Marabelle, Manuel RodriguesManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Stéphane ChampiatHonoraria: Amgen, AstraZeneca, Bristol Myers Squibb, MSD, Novartis, Roche, Fresenius Kabi, Eisai Europe, Genmab, Janssen, Merck KGaA, Merck SeronoConsulting or Advisory Role: Alderaan Biotechnology, Amgen, AstraZeneca, Avacta Life Sciences, Celanese, Domain Therapeutics, Ellipses Pharma, Genmab, Immunicom, Nanobiotix, Oncovita, Pierre Fabre, Seagen, Tatum Bioscience, Tollys, UltraHuman8, NextCure, BioNTech SEResearch Funding: AstraZeneca (Inst), Bristol Myers Squibb (Inst), Boehringer Ingelheim (Inst), Janssen-Cilag (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Roche (Inst), Sanofi (Inst), AbbVie (Inst), Adaptimmune (Inst), Aduro Biotech (Inst), Agios (Inst), Amgen (Inst), arGEN-X BVBA (Inst), Arno Therapeutics (Inst), Astex Pharmaceuticals (Inst), AstraZeneca (Inst), Bayer (Inst), BB Biotech Ventures (Inst), BeiGene (Inst), BioAlliance Pharma (Inst), BioNTech (Inst), Blueprint Medicines (Inst), Boehringer Ingelheim (Inst), Boston Pharmaceuticals (Inst), Bristol Myers Squibb (Inst), Celgene (Inst), Cephalon (Inst), Chugai Pharma (Inst), Clovis Oncology (Inst), Cullinan Oncology (Inst), Daiichi Sankyo (Inst), Debiopharm Group (Inst), Eisai (Inst), Lilly (Inst), Exelixis (Inst), FORMA Therapeutics (Inst), GamaMabs Pharma (Inst), Genentech (Inst), Gilead Sciences (Inst), GlaxoSmithKline (Inst), Glenmark (Inst), H3 Biomedicine (Inst), Roche (Inst), Incyte (Inst), Innate Pharma (Inst), Pierre Fabre (Inst), Servier (Inst), Janssen-Cilag (Inst), Kura Oncology (Inst), Kyowa Hakko Kirin (Inst), Loxo (Inst), Lytix Biopharma (Inst), MedImmune (Inst), Menarini (Inst), Merck KGaA (Inst), Merck Sharp & Dohme (Inst), Merrimack (Inst), Merus (Inst), Millennium (Inst), Molecular Partners (Inst), Nanobiotix (Inst), Nektar (Inst), Nerviano Medical Sciences (Inst), Novartis (Inst), Octimet (Inst), OncoEthix (Inst), OncoMed (Inst), Oncopeptides (Inst), Onyx (Inst), Orion (Inst), Oryzon Genomics (Inst), Ose Pharma (Inst), Pfizer (Inst), PharmaMar (Inst), Philogen (Inst), Pierre Fabre (Inst), Plexxikon (Inst), RigonTEC (Inst), Sanofi/Aventis (Inst), Sierra Oncology (Inst), Sotio (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), Tesaro (Inst), Tioma Therapeutics (Inst), Wyeth (Inst), Xencor (Inst), Y's Therapeutics (Inst), Cytovation, Eisai/H3 Biomedicine, ImCheck therapeutics, Molecular Partners, MSD, OSE Immunotherapeutics, Pierre Fabre, Sanofi, Sotio, Transgene, Boehringer Ingelheim, AbbVie, Amgen, Adlai Nortye (Inst), AVEO (Inst), Basilea Pharmaceutical (Inst), BBB Technologies (Inst), Bicycle Therapeutics (Inst), CASI Pharmaceuticals (Inst), CellCentric (Inst), CureVac (Inst), Faron Pharmaceuticals (Inst), ITeos Therapeutics (Inst), Relay Therapeutics (Inst), Seagen (Inst), Transgene (Inst), Turning Point Therapeutics (Inst), GlaxoSmithKline (Inst)Patents, Royalties, Other Intellectual Property: T-cell immunogens derived from anti-viral proteins and methods of using same WO2010039223A2Travel, Accommodations, Expenses: MSD, AstraZeneca, Amgen, Bristol Myers Squibb, Merck, OSE Immunotherapeutics, Roche, SotioOther Relationship: AstraZeneca (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Boehringer Ingelheim (Inst), Boehringer Ingelheim (Inst), Johnson & Johnson (Inst), Lilly (Inst), MedImmune (Inst), Merck (Inst), Pfizer (Inst), Roche (Inst), Roche (Inst), GlaxoSmithKline (Inst), NH TherAguix (Inst)Hélène SalaünTravel, Accommodations, Expenses: PfizerBenjamin BesseResearch Funding: AstraZeneca (Inst), Inivata (Inst), AbbVie (Inst), Amgen (Inst), Sanofi (Inst), Daiichi Sankyo (Inst), Janssen Oncology (Inst), Roche/Genentech (Inst), Aptitude Health (Inst), Chugai Pharma (Inst), Genzyme (Inst), Ipsen (Inst), Turning Point Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Genmab (Inst), Genzyme (Inst), Hedera Dx (Inst), MSD Oncology (Inst), PharmaMar (Inst), Taiho Pharmaceutical (Inst), Socar (Inst)Etienne RouleauHonoraria: AstraZeneca (Inst), Roche (Inst), BMS (Inst), GlaxoSmithKline (Inst), Clovis Oncology (Inst), MSD Oncology (Inst), MSD Oncology (Inst), MSD Oncology (Inst)Consulting or Advisory Role: AstraZenecaResearch Funding: AstraZeneca (Inst)Travel, Accommodations, Expenses: AstraZeneca, BMSMathilde Saint-GhislainHonoraria: OncostreamNathalie CassouxTravel, Accommodations, Expenses: FCI (Inst)Marc-Henri SternHonoraria: GlaxoSmithKlineConsulting or Advisory Role: GlaxoSmithKlineResearch Funding: Bionano Genomics (Inst)Patents, Royalties, Other Intellectual Property: Royalties on the licensing of the HRD patent included in the myChoice HRD test (Inst)Olivier LantzHonoraria: BiomunexResearch Funding: Biomunex (Inst), Transgene (Inst)Patents, Royalties, Other Intellectual Property: BioLegend royalties for 3C10 antibody (Inst)Aurélien MarabelleStock and Other Ownership Interests: Shattuck Labs, Centessa Pharmaceuticals, Deka Biosciences, HotSpot Therapeutics, Marengo TherapeuticsConsulting or Advisory Role: Lytix Biopharma, EISAI, Pierre Fabre, AstraZeneca, Servier, Roche, Redx Pharma, Sotio, Innate Pharma, ImCheck therapeutics, MSD, OSE Immunotherapeutics, HiFiBiO Therapeutics, Centessa Pharmaceuticals, Clover Biopharmaceuticals, Shattuck Labs, Deka Biosciences, Hotspot Therapeutics, Medicxi, Depth Charge Therapeutics, BioLineRx, Gritstone Bio, Johnson & Johnson/Janssen, Third Rock Ventures, Sanofi, PegaOne, Guidepoint Global, Neogene Therapeutics, Gray Wolf Therapeutics, AdageneResearch Funding: Bristol Myers Squibb (Inst), Boehringer Ingelheim (Inst), Transgene (Inst), MSD (Inst)Patents, Royalties, Other Intellectual Property: Monoclonal antibodies against CD81 (Stanford University)Travel, Accommodations, Expenses: SotioOther Relationship: ElsevierManuel RodriguesHonoraria: ImmunocoreConsulting or Advisory Role: AstraZeneca, GlaxoSmithKlineResearch Funding: Daiichi Sankyo/AstraZenecaTravel, Accommodations, Expenses: AstraZenecaNo other potential conflicts of interest were reported.